Compare Stocks: LENZ, OVID, CTNM, and AQST

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AQST Aquestive Therapeutics	$4.32 +0.7%	$4.15	$2.93 ▼ $7.55	$533.42M	1.49	3.06 million shs	5.45 million shs
CTNM Contineum Therapeutics	$14.50 -0.2%	$14.20	$8.12 ▼ $16.91	$533.84M	0.74	374,140 shs	531,007 shs
LENZ LENZ Therapeutics	$4.77 -0.4%	$5.56	$4.53 ▼ $50.40	$150.50M	0.65	885,833 shs	534,396 shs
OVID Ovid Therapeutics	$2.84 -1.7%	$2.49	$0.84 ▼ $3.11	$552.69M	0.21	1.52 million shs	1.94 million shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AQST Aquestive Therapeutics	+0.70%	-2.04%	+4.85%	+3.60%	+3.35%
CTNM Contineum Therapeutics	-0.21%	-2.16%	+1.90%	+8.29%	+79.01%
LENZ LENZ Therapeutics	-0.42%	-8.45%	-7.92%	-33.75%	-87.70%
OVID Ovid Therapeutics	-1.73%	+10.08%	+16.39%	+18.83%	+205.38%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AQST Aquestive Therapeutics	$4.32 +0.7%	$4.15	$2.93 ▼ $7.55	$533.42M	1.49	3.06 million shs	5.45 million shs
CTNM Contineum Therapeutics	$14.50 -0.2%	$14.20	$8.12 ▼ $16.91	$533.84M	0.74	374,140 shs	531,007 shs
LENZ LENZ Therapeutics	$4.77 -0.4%	$5.56	$4.53 ▼ $50.40	$150.50M	0.65	885,833 shs	534,396 shs
OVID Ovid Therapeutics	$2.84 -1.7%	$2.49	$0.84 ▼ $3.11	$552.69M	0.21	1.52 million shs	1.94 million shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AQST Aquestive Therapeutics	+0.70%	-2.04%	+4.85%	+3.60%	+3.35%
CTNM Contineum Therapeutics	-0.21%	-2.16%	+1.90%	+8.29%	+79.01%
LENZ LENZ Therapeutics	-0.42%	-8.45%	-7.92%	-33.75%	-87.70%
OVID Ovid Therapeutics	-1.73%	+10.08%	+16.39%	+18.83%	+205.38%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AQST Aquestive Therapeutics	3.00	Buy	$8.50	96.76% Upside
CTNM Contineum Therapeutics	2.40	Hold	$20.25	39.66% Upside
LENZ LENZ Therapeutics	2.50	Moderate Buy	$28.80	503.77% Upside
OVID Ovid Therapeutics	2.89	Moderate Buy	$5.71	101.21% Upside

Current Analyst Ratings Breakdown

Latest LENZ, OVID, CTNM, and AQST Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2026	LENZ LENZ Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/12/2026	LENZ LENZ Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Neutral	$12.00 ➝ $7.00
8/12/2026	LENZ LENZ Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/11/2026	LENZ LENZ Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/3/2026	OVID Ovid Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$7.00 ➝ $9.00
7/31/2026	CTNM Contineum Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$22.00 ➝ $23.00
7/21/2026	OVID Ovid Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/17/2026	AQST Aquestive Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	CTNM Contineum Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	OVID Ovid Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/15/2026	LENZ LENZ Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell

(Data available from 8/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AQST Aquestive Therapeutics	$44.54M	12.17	N/A	N/A	($0.28) per share	-15.43
CTNM Contineum Therapeutics	$50M	10.91	N/A	N/A	$6.99 per share	2.07
LENZ LENZ Therapeutics	$21.48M	6.98	N/A	N/A	$9.09 per share	0.52
OVID Ovid Therapeutics	$7.25M	76.50	N/A	N/A	$1.00 per share	2.84

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AQST Aquestive Therapeutics	-$83.78M	-$0.65	N/A	N/A	N/A	-144.63%	N/A	-52.40%	11/4/2026 (Estimated)
CTNM Contineum Therapeutics	-$59.98M	-$1.73	N/A	N/A	N/A	N/A	-24.73%	-23.51%	10/29/2026 (Estimated)
LENZ LENZ Therapeutics	-$82.13M	-$4.09	N/A	N/A	N/A	-586.74%	-53.39%	-49.14%	11/4/2026 (Estimated)
OVID Ovid Therapeutics	-$17.41M	-$0.31	N/A	N/A	N/A	-240.11%	-23.64%	-20.52%	N/A

Latest LENZ, OVID, CTNM, and AQST Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	OVID Ovid Therapeutics	-$0.1150	-$0.08	+$0.0350	-$0.08	$0.02 million	$0.73 million
8/11/2026	Q2 2026	AQST Aquestive Therapeutics	-$0.1050	-$0.18	-$0.0750	-$0.18	$11.42 million	$13.82 million
8/11/2026	Q2 2026	LENZ LENZ Therapeutics	-$1.05	-$1.02	+$0.03	-$1.02	$2.38 million	$5.49 million
7/30/2026	Q2 2026	CTNM Contineum Therapeutics	-$0.4488	-$0.40	+$0.0488	-$0.40	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AQST Aquestive Therapeutics	N/A	N/A	N/A	N/A	N/A
CTNM Contineum Therapeutics	N/A	N/A	N/A	N/A	N/A
LENZ LENZ Therapeutics	N/A	N/A	N/A	N/A	N/A
OVID Ovid Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AQST Aquestive Therapeutics	N/A	7.19	6.74
CTNM Contineum Therapeutics	N/A	37.17	37.17
LENZ LENZ Therapeutics	N/A	13.55	13.31
OVID Ovid Therapeutics	0.05	12.39	12.39

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AQST Aquestive Therapeutics	32.45%
CTNM Contineum Therapeutics	N/A
LENZ LENZ Therapeutics	54.32%
OVID Ovid Therapeutics	72.24%

Insider Ownership

Company	Insider Ownership
AQST Aquestive Therapeutics	6.81%
CTNM Contineum Therapeutics	7.90%
LENZ LENZ Therapeutics	8.30%
OVID Ovid Therapeutics	7.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AQST Aquestive Therapeutics	160	125.51 million	116.97 million	Optionable
CTNM Contineum Therapeutics	31	37.62 million	34.65 million	N/A
LENZ LENZ Therapeutics	110	31.42 million	28.81 million	N/A
OVID Ovid Therapeutics	60	195.30 million	181.63 million	Optionable

LENZ, OVID, CTNM, and AQST Headlines

Recent News About These Companies

What Makes Ovid Therapeutics (OVID) a Strong Momentum Stock: Buy Now?

August 18 at 1:01 PM | zacks.com

Ovid Therapeutics: Buy Rating on Advancing OV329 Seizure Pipeline and Strong Cash Runway Through 2029

August 17 at 6:30 AM | tipranks.com

Ovid Therapeutics (NASDAQ:OVID) Stock Rating Upgraded by Wall Street Zen

August 15, 2026 | americanbankingnews.com

Ovid Therapeutics (NASDAQ:OVID) Raised to Hold at Wall Street Zen

August 15, 2026 | marketbeat.com

Ovid Therapeutics (NASDAQ:OVID) Shares Up 9% on Better-Than-Expected Earnings

August 15, 2026 | americanbankingnews.com

Soticlestat revived: Perceptive Advisors bets FDA rejected trial design, not drug itself

August 14, 2026 | msn.com

Reiterated Buy Rating on Ovid Therapeutics as Solid Pipeline Execution and Two-Year Cash Runway Support Unchanged $5 Price Target

August 14, 2026 | tipranks.com

Ovid Therapeutics (NASDAQ:OVID) Announces Earnings Results, Beats Estimates By $0.02 EPS

August 13, 2026 | marketbeat.com

Ovid Therapeutics: Buy Rating Backed by De-Risked Balance Sheet and Differentiated Epilepsy Pipeline (OV329, OV4071)

August 13, 2026 | tipranks.com

Ovid Therapeutics (NASDAQ:OVID) Stock Price Up 9% Following Better-Than-Expected Earnings

August 13, 2026 | marketbeat.com

Ovid Therapeutics (OVID) Reports Q2 Loss, Beats Revenue Estimates

August 13, 2026 | zacks.com

Ovid Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results

August 13, 2026 | globenewswire.com

Ovid Therapeutics (OVID) to Release Earnings on Wednesday

August 11, 2026 | americanbankingnews.com

Earnings Preview: Ovid Therapeutics (OVID) Q2 Earnings Expected to Decline

August 5, 2026 | zacks.com

Ovid Therapeutics (OVID) Expected to Release Quarterly Earnings on Wednesday

August 5, 2026 | marketbeat.com

Janus Henderson Group PLC Takes $23.73 Million Position in Ovid Therapeutics $OVID

August 4, 2026 | marketbeat.com

Ovid Therapeutics (NASDAQ:OVID) Given New $9.00 Price Target at Oppenheimer

August 3, 2026 | marketbeat.com

Ally Bridge Group NY LLC Has $6.26 Million Position in Ovid Therapeutics $OVID

July 29, 2026 | marketbeat.com

Ovid Therapeutics (NASDAQ:OVID) Given Consensus Rating of "Moderate Buy" by Brokerages

July 29, 2026 | marketbeat.com

Affinity Asset Advisors LLC Acquires 3,486,318 Shares of Ovid Therapeutics $OVID

July 25, 2026 | marketbeat.com

Ovid Therapeutics (NASDAQ:OVID) Downgraded by Wall Street Zen to "Sell"

July 25, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

LENZ, OVID, CTNM, and AQST Company Descriptions

Aquestive Therapeutics NASDAQ:AQST

$4.32 +0.03 (+0.70%)

Closing price 08/18/2026 04:00 PM Eastern

Extended Trading

$4.33 +0.01 (+0.23%)

As of 08/18/2026 07:44 PM Eastern

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

Contineum Therapeutics NASDAQ:CTNM

$14.50 -0.03 (-0.21%)

Closing price 08/18/2026 04:00 PM Eastern

Extended Trading

$14.50 -0.01 (-0.03%)

As of 08/18/2026 07:30 PM Eastern

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.

LENZ Therapeutics NASDAQ:LENZ

$4.77 -0.02 (-0.42%)

Closing price 08/18/2026 04:00 PM Eastern

Extended Trading

$4.78 +0.01 (+0.27%)

As of 08/18/2026 07:59 PM Eastern

LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

Ovid Therapeutics NASDAQ:OVID

$2.84 -0.05 (-1.73%)

Closing price 08/18/2026 04:00 PM Eastern

Extended Trading

$2.84 +0.01 (+0.18%)

As of 08/18/2026 07:52 PM Eastern

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LENZ, OVID, CTNM, and AQST Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LENZ, OVID, CTNM, and AQST Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LENZ, OVID, CTNM, and AQST Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

LENZ, OVID, CTNM, and AQST Company Descriptions

Aquestive Therapeutics NASDAQ:AQST

Contineum Therapeutics NASDAQ:CTNM

LENZ Therapeutics NASDAQ:LENZ

Ovid Therapeutics NASDAQ:OVID

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LENZ, OVID, CTNM, and AQST Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LENZ, OVID, CTNM, and AQST Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LENZ, OVID, CTNM, and AQST Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

LENZ, OVID, CTNM, and AQST Company Descriptions

Aquestive Therapeutics NASDAQ:AQST

Contineum Therapeutics NASDAQ:CTNM

LENZ Therapeutics NASDAQ:LENZ

Ovid Therapeutics NASDAQ:OVID

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools